Posters
« Back
Gender and Race Differences in Deceased Donor Hypertension for Kidney Transplantation
EP25570
Gender and Race Differences in Deceased Donor Hypertension for Kidney Transplantation
Submitted on 15 Feb 2017

Dylan Lahiff, Talha Rashid, Ebonie Rogers, Victor Bowers, M.D., Jacentha Buggs, M.D., Fern Webb, M.D.
University of South Florida, Tampa, Florida, 2. Tampa General Medical Group, Tampa, Florida, 3. University of Florida, Jacksonville, Florida
This poster was presented at USF Health Research Day 2017
Poster Views: 295
View poster »
Poster Abstract
Introduction: Approximately 70 million American adults (29%) have hypertension (HTN), a leading cause of heart disease and stroke. Nearly 360,000 Americans die each year from stroke resulting from HTN (1 in 20 deaths). Many deceased stroke victims donate their organs for transplantation. Hypothesis: We hypothesized that both HTN and cerebrovascular/stroke (CVS) cause of death (COD) in the donor population mirrors that of the general population. Methods: We analyzed adult deceased kidney donors (ADKD) from both our local and the nationwide population-based (United Network for Organ Sharing) databases from 2011 to 2015. Results: At our center, a total of n = 346 ADKD provided the gift of life to 492 kidney transplant recipient adults over the age of 18. The average donor age was 41.5 (SEM 0.76). The donor gender distribution was 215 male (62.1%) and 131 female (37.9%). The donor racial composition included Caucasians (72%), African Americans (11%), Hispanics (16%), Asians (1%) and other racial groups (< 1%). Stroke as the donor COD occurred in 32% of patients. There was a significant association in the prevalence of HTN among donors dying from CVS among local donors (Χ2=27.27; p < .0001). There was no significant difference in mean 1 year patient survival (t value = 0.54; p= 0.59) or graft survival (t value = -0.10; p= 0. 92) among patients receiving organs from donors with or without HTN. The national data contained n = 20,017 ADKD with 6,420 (32.1%) donors having CVS as the COD. The average national donor age was 40.6 (SEM 0.09). The national donor gender distribution was 12,098 male (60.4%) and 7,919 female (39.6%). The national racial composition included 13,759 Caucasians (68.7%), 2,719 African Americans (13.6%), 2,672 Hispanics (13.4%), 499 Asians (2.5%) and 374 individuals from other racial backgrounds (1.8%). There was a significant association in the prevalence of HTN among donors dying from CVS as the COD (Χ2=2297; p < .0001) among national donors. Conclusion: HTN and cerebrovascular/stroke as the COD in both the local and national donor populations are reflective of the general population. Intentional effort should be devoted to tracking and comparing results between these populations as nationwide efforts to treat HTN and prevent stroke continue to improve.

1. Tatiana Nwankwo MSSSSY, Ph. D., R.N.; Vicki Burt, Sc.M., R.N.; and Qiuping Gu, M.D., Ph.D. Hypertension Among Adults in the United States: National Health adn Nurtrition Examination Survey, 2011-2012. U.S. Department of Health and Human Services;2013.
2. U.S. Department of health and Human Services OoDPaHP. Healthy People 2020. http://www.healthypeople.gov/2020/default.aspx, 2013.
3. CDC CfMMS. Million Hearts Initiative. http://millionhearts.hhs.gov/index.html, 2013.
4. Ong KL, Tso AW, Lam KS, Cheung BM. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension. Apr 2008;51(4):1142-1148.
5. Yoon SS, National Center for Health Statistics (U.S.). Hypertension among adults in the United States, 2009-2010.
6. Keenan NL, Rosendorf KA, Centers for Disease C, Prevention. Prevalence of hypertension and controlled hypertension - United States, 2005-2008. MMWR supplements. Jan 14 2011;60(1):9
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


MODEL-AD: Bioinformatics and Data ManagementMODEL-AD: Bioinformatics and Data Management
Bruce Lamb1, Michael Sasner2, Andrew Saykin1, Lara Mangravite3, Gregory Carter2

MODEL-AD: The Disease Modeling Project
M.Sasner1, A. Oblak2, H. Williams1, G. Howell1, B.T. Lamb2 and the MODEL-AD consortium

MODEL-AD: Genetic models of late-onset Alzheimer’s disease
*A. OBLAK1,2, G. CARTER3, G. R. HOWELL3, B. LOGSDON4, L. MANGRAVITE4, K. NHO2, L. OMBERG4, K. D. ONOS3, V. PHILIP3, C. PREUSS3, S. J. SUKOFF RIZZO3, M. SASNER3, L. SHEN1,2, A. J. SAYKIN1,2, P. TERRITO1,2, A. UYAR3, H. WILLIAMS3, B. T. LAMB1,5

Preclinical drug screening in new generation Alzheimer’s disease mouse models: The MODEL-AD Consortium Strategy
P.R. Territo1, S.J. Sukoff Rizzo2, K. Onos2, J.A. Meyer1, J. Peters1, S.C. Persohn1, B.R. McCarthy1, A.A. Riley1, S. Quinney1, D. Jones1, M. Sasner2, G. Howell2, H. Williams2, A.J. Oblak1, B.L. Lamb1 and the MODEL-AD consortium

Association of Nonalcoholic Fatty Liver Disease with Insulin Resistance in Type 2 Diabetes Mellitus – A prospective study
Jasim Jalal; Shobha P; Nisha N; Shani Basheer; Nelson Joseph